In the third quarter of 2025, Clariane achieved a revenue of 1,320 million euros, marking a 5.1% organic increase compared to the same period in 2024. Over the first nine months of the year, the revenue amounted to 3,976 million euros, showing a 4.9% organic growth. This growth is attributed to all regions and business sectors of the company.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The company continues to improve its pricing and product mix. For the second half of 2025, the company anticipates an EBITDA growth, although the target is slightly below the initial range of 6% to 9%.
Clariane finalized its financial strengthening plan earlier than anticipated. The company expects a continued increase in volumes and pricing adjustments, particularly in Germany. For 2025, it confirms its organic revenue growth target of around 5% and aims to reduce its financial leverage to less than 5.5 times EBITDA. The outlook for 2026 includes an improvement in EBITDA margin.
SectorSanté · Etablissements de santé / EHPAD›Etablissements de santé
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1336M€
Guidance from the release
Avec une croissance organique de 4,9 %, le premier trimestre 2026 s’inscrit pleinement dans la dynamique.
Le chiffre d’affaires au 31 mars 2026 s’établit à €1 336m, en progression de +4,9%.
Risks mentioned
Impact des cessions intervenues en 2025 dans le cadre du plan de renforcement.
Risque lié aux conditions de marché futures.
Effets des défis réglementaires dans le secteur.
Opportunities identified
Lancement d'une obligation senior de €500m à échéance 2031.
Nouvelle dynamiqueprix/volume grâce aux mesures d’adaptation mises en place.
Engagement fort des collaborateurs pour atteindre les objectifs opérationnels.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
